Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 592 results for women's health

  1. Diabetes in pregnancy (QS109)

    This quality standard covers managing diabetes and its complications in women who are planning a pregnancy or are already pregnant. It includes care for women with pre-existing diabetes before and during pregnancy, and diagnosis and management of gestational diabetes. It describes high-quality care in priority areas for improvement.

  2. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  3. Thyroid cancer: assessment and management (NG230)

    This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.

  4. Tobacco: treating dependence (QS207)

    This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.

  5. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

  6. Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)

    Evidence-based recommendations on amivantamab (Rybrevant) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults.

  7. NICE impact people with a learning disability

    highlights the lack of progress made in many areas. Data shows high levels of health inequality and limited positive change over time....

  8. NICE impact cardiovascular disease prevention

    Find out more about the progress made in implementing NICE guidance on cardiovascular disease prevention

  9. Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (NG228)

    This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure that the most effective treatments are offered. It includes guidance on follow-up care and information for people (aged 16 and over) who have had an aneurysmal subarachnoid haemorrhage, their families and carers.

  10. Targeted treatment for rare form of aggressive lung cancer gets NICE approval

    Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer

  11. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

  12. Maternity and mental health

    newborns Women can develop mental ill health for the first time during pregnancy, and pre-existing mental...

  13. Specialist care of newborns

    NICEimpact maternity and neonatal care Previous: Maternity and mental health Next: Spotlight on valproate prescribing Newborn

  14. Commentary - maternity and neonatal care

    way that would have been unthinkable to our grandparents. This means that women and their partners have higher expectations about the...

  15. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA836)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.